AbbVie Inc. Form SCHEDULE 13G: Beneficial ownership report (passive)
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-04-29: Form SCHEDULE 13G; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X02/primary_doc.xml.
- 2026-03-26: Form SCHEDULE 13G/A; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X02/primary_doc.xml.
- 2025-07-07: Form SCHEDULE 13G/A; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X01/primary_doc.xml.
- 2025-02-18: Form SCHEDULE 13G; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X01/primary_doc.xml.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-04-29 | SCHEDULE 13G | Beneficial ownership report (passive) | xslSCHEDULE_13G_X02/primary_doc.xml | |
| 2026-03-26 | SCHEDULE 13G/A | Beneficial ownership report (passive) | xslSCHEDULE_13G_X02/primary_doc.xml | |
| 2025-07-07 | SCHEDULE 13G/A | Beneficial ownership report (passive) | xslSCHEDULE_13G_X01/primary_doc.xml | |
| 2025-02-18 | SCHEDULE 13G | Beneficial ownership report (passive) | xslSCHEDULE_13G_X01/primary_doc.xml |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |